StockData
Veracyte, Inc. logo

Veracyte, Inc. (VCYT) stock

VCYTNasdaqServices-Medical LaboratoriesFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Nov 5, 2026Score 16/3034% below fair value
$25.57+1.34 (+5.53%)

Close on Nov 18, 2026Market cap $2.06BP/E 18.3Yield –

Veracyte price to book ratio

The price-to-book ratio is market cap divided by shareholders' equity.

Veracyte's price to book ratio was 1.5× on Nov 11, 2026, against 3.0× a year earlier. Over the last 5 years it ranged from 1.1× to 3.5×, with a median of 1.8×.

Price to Book Ratio at the end of each year

PeriodPeriod endValueChange (pts)
2026Nov 11, 20261.5×−1.2
2025Dec 31, 20252.6×+0.0
2024Dec 31, 20242.6×+0.7
2023Dec 29, 20231.9×+0.3
2022Dec 30, 20221.6×−1.0
2021Dec 31, 20212.6×−4.0
2020Dec 31, 20206.7×+0.8
2019Dec 31, 20195.9×−0.5
2018Dec 31, 20186.4×+1.2
2017Dec 29, 20175.2×−2.0
2016Dec 30, 20167.2×+3.8
2015Dec 31, 20153.4×−1.1
2014Dec 31, 20144.5×–

More Veracyte figures

See a number that looks wrong?